Successful Re-Administration of Low-Dose of Methimazole (MMI) in Graves' Disease Patients who Experienced Allergic Cutaneous Reactions to MMI at Initial Treatment and Had Received Long-Term Propylthiouracil (PTU) | oneGRAVESvoice

welcome to oneGRAVESvoice

- a positively charged Graves' disease and thyroid eye disease community.
  • join today!
Scientific Articles

Successful Re-Administration of Low-Dose of Methimazole (MMI) in Graves’ Disease Patients who Experienced Allergic Cutaneous Reactions to MMI at Initial Treatment and Had Received Long-Term Propylthiouracil (PTU)

key information

source: Internal Medicine

year: 2016

authors: Kubota S

summary/abstract:

Objective:
When patients with Graves’ disease show severe allergic cutaneous reactions, physicians often suggest that they undergo radioiodine therapy instead of receiving propylthiouracil (PTU), another antithyroid drug, because anti-neutrophil cytoplasmic antibody (ANCA) -related vasculitis can occur with PTU, especially with long-term use. However, some patients refuse radioiodine therapy and chose PTU. Sometimes PTU treatment may be prolonged. Since the frequency of adverse effects of methimazole (MMI) is dose-related, there is a possibility that we can re-administer a low dose without adverse effects to patients well-controlled with PTU who once experienced an allergic reaction to MMI.

Methods:
I prospectively re-administered a low dose of MMI to patients who previously experienced an allergic reaction to MMI at initial treatment. The dose of re-administered MMI ranged from 5 mg twice a week to 5 mg daily.

Patients:
Nine patients with Graves’ disease who developed urticaria at initial treatment with MMI and had been treated with PTU for 6 to 21 years were recruited.

Results:
Eight of the 9 patients were successfully controlled with MMI without allergic cutaneous reactions. Only one patient felt itchiness 2 days after switching to MMI. However, skin change was not observed.

Conclusion:
If the patients show allergic cutaneous reactions as a side effect of MMI at the initial treatment for Graves’ disease, then there is a strong possibility that such patients can tolerate a low dose of MMI without adverse effects after the disease activity has subsided.

organization: Kubota Thyroid Clinic, Japan

DOI: 10.2169/internalmedicine.55.7281

full text source
Font Resize

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close